Skip to main content
PMC home page
Medical Journal of the Islamic Republic of Iran logoLink to Medical Journal of the Islamic Republic of Iran
. 2018 Jul 2;32:55. doi: 10.14196/mjiri.32.55

Burden of esophageal cancer in Iran during 1995-2015: Review of findings from the Global Burden of Disease studies

Hojjat Rahmani 1, Ali Sarabi Asiabar 2, Somayeh Niakan 3, Seyed Yaser Hashemi 4, Ahmad Faramarzi 5,*, Sahar Manuchehri 1, GHasem Rajabi Vasokolaei 1,6
PMCID: PMC6113580  PMID: 30175081

Abstract

Background: Iran is located in Asian esophageal cancer belt, with age-standardized incidence rate (ASR) of approximately 7 per 100,000 for both men and women. To provide potential solution recommendations for achieving accurate estimations regarding the burden of the disease in Iran, we designed a study to assess the burden of esophageal cancer in Iran during 1995-2015 by collecting data from the Global Burden of Disease studies.

Methods: Data were extracted from the Global Burden of Disease (GBD) during 1995-2015, which were published by the Institute for Health Metrics and Evaluation. For this purpose, disability adjusted life years (DALYs), incidence, and prevalence rate were applied to report burden of esophageal cancer based on gender and age group in Iran during 1995-2015. The Cochran-Armitage and t test were used to assess statistical significance. Stata Version 13 and Excel 2016 were used for data analysis.

Results: During 1995-2015, in total, 304 102 DALYs (179 562 for males vs. 124 540 for females) were attributed to esophageal cancer in Iran. In both genders and all ages, the number of DALYs increased significantly from 45 018 in 1995 to 74 399 in 2015.

Conclusion: Esophageal cancer is still a public health issue in Iran. Most of DALYs were due to years of life lost (YLL), suggesting the need for prevention, early detection, and screening programs. P-value was statistically significant just between male and female groups (p<0.05).

Keywords: Esophageal cancer, Disability adjusted life years, Iran, Global burden of disease

↑ What is “already known” in this topic:

In the last decade, the burden of esophageal cancer has increased in Iran, especially in males, and this cancer was the sixth most common cause of mortality due to cancer worldwide.

→ What this article adds:

Esophageal cancer is common in Iran, and the majority of DALY due to esophageal cancer is related to 50-69 age group. The burden of esophageal cancer is significantly higher in males.

Introduction

Esophageal cancer is considered as a fatal disease in developed and developing countries. This health problem is the sixth most common cause of mortality due to cancer worldwide, with estimated 439 025 deaths in 2015 (1-3). Based on GLOBOCAN 2012 data, the estimated mortality rate of esophageal cancer is 14.1 per 100 000 in Eastern Asia, 12.8 in males in Southern Africa, 7.3 in Eastern Africa, and 6.2 in females in Southern Africa (1).

Iran is a country located in Asian esophageal cancer belt, with age-standardized incidence rates (ASR) of approximately 7 per 100 000 for males and females, which even exceeds 100 in its high-risk area (4-6). For instance, in Golestan province, in the eastern part of the Caspian littoral of Iran, the age-adjusted incidence rate has been reported to be 100 per 100 000 (World Standard Population) in the 1960s and 1970s for both genders. Other studies also showed age-standardized incidence rates of 43.4 and 36.3 for males and females, respectively during 1996-2000 (7, 8). Esophageal cancer is responsible for almost 5800 of 35 000 annual cancer deaths in Iran (9). Although survival rate for cancers has been improving in recent years, esophageal cancer remains one of the most fatal malignancies. This cancer is diagnosed at a late stage, with 5-year survival rate of 10% and 14% for males and females, respectively, in Iran and 12% in Europe (10-12).

According to the literature relevant to esophageal cancer in Iran, studies that calculated the burden of esophageal cancer are divided into 2 groups. The first group, which is also the main group, includes studies using the number of deaths, prevalence, incidence rate, and mortality rate as indicators. These studies were designed to evaluate the epidemiology of esophageal cancer and examine the incidence, prevalence, and mortality due to cancers (13-16). The second group included studies concerning disability adjusted life years (DALYs), years of life lost (YLLs), and years lost due to disability (YLD) as health gap indicators. Unlike the first group studies, these studies are rare and have been conducted at regional levels (17, 18).

Esophageal cancer has put an extensive burden on the health, life expectancy, and well-being of Iranian population, especially in northern areas. Moreover, few studies have examined the burden of disease in the general population. Therefore, the present study was conducted to report the burden of esophageal cancer in Iran during 1995-2015 by acquiring data from Global Burden of Disease (GBD). Furthermore, the aim of this study was to describe the burden of esophageal cancer via DALY approach, which has introduced GBD methods and is also helpful for health policy-makers. Cancer burden studies are potentially important in public health decision-making because they help detect improvements in information systems and cost-effectiveness studies.

Methods

Data were retrospectively collected from the Global Burden of Disease (GBD) during 1995-2015 and published by the Institute for Health Metrics and Evaluation (IHME). In the GBD, data are collected and analyzed by a consortium of more than 1800 researchers in more than 120 countries. Preliminary data included premature death and disability from more than 300 diseases and injuries in 20 groups separated by age and sex in 188 countries during 1990-2018. In GBD studies, a comprehensive database of death registration system, vital registration, verbal autopsy, mortality surveillance, and other sources is used to assess the outcomes of health loss, including deaths and death rates, YLLs, YLDs, and DALYs. A complete description of the data, statistical modeling, and metrics are explained in detail elsewhere (19-21).

To better characterize the burden of esophageal cancer in Iran, we needed to collect reported death number and crude incidence and prevalence rate. The incidence rate refers to the number of new cases in a fixed time period divided by the number of people at risk. On the other hand, the prevalence rate is the number of people with the disease at a given time divided by the number of people at risk. DALY is a tool developed by the World Health Organization (WHO) to measure, compare, and analyze the burden of various diseases (22, 23). The DALY combines time lost through premature death and time lived in states of less than optimal health, generally referred to as disability. This metric contains 2 components: years of life lost due to premature mortality (YLLs) and number of years lost due to disability (YLDs). A DALY is equal to the loss of one year of healthy life from the combined impacts of mortality and disability (24, 25).

The YLLs for a cause are basically calculated through the number of cause-specific deaths in an age group multiplied by a standard life expectancy at which death occurs (26). The YLDs for a particular cause were calculated by multiplying the number of incident cases by the disability weight by the average duration of the case until remission or death. The weight of disability has been reported by the WHO studies for various diseases (27, 28).

Stata Version 13 and Excel 2016 were used to analyze data and report DALY numbers and its components based on gender and age group during 1995-2015. To assess statistical significance according to trend, the Cochran-Armitage test was applied. Also, t test was used to analyze gender groups, with significance level set at p<0.05. The age groups were categorized according to the method proposed by WHO and other studies. These groups include younger than 5 years, 5-14 years, 15-49 years, 50-69 years, and older than 70 years (29).

Results

GBD results for esophageal cancer in Iran are presented here based on the following parameters: The disability-adjusted life years (DALYs), years of life lost due to premature mortality (YLLs), number of years lost due to disability (YLDs), death, incidence, and prevalence rate.

During 1995-2015, there were 13 144 deaths related to esophageal cancer in Iran. The number of deaths caused by esophageal cancer increased in Iran from 1853 in 1995 to 3261 in 2015 in both genders. Table 1 demonstrates death number, incidence, and prevalence rate per 100 000 due to esophageal cancer in Iran.

Table 1. The number of death, incidence, and prevalence rate of esophageal cancer in Iran during 1995- 2015 .

Years Death Number Crude Incidence Per 100 000 Crude Prevalence Per 100 000
Male Female Both p Male Female Both p Male Female Both p
1995 1099 754 1853 0.004 3.12 2.26 2.7 0.003 3.33 2.58 2.96 0.009
2000 1282 883 2165 3.49 2.57 3.04 4.02 3.28 3.66
2005 1726 1187 2913 4.55 3.38 3.98 5.62 4.72 5.18
2010 1775 1177 2952 4.69 3.3 4 6.14 4.93 5.54
2015 2085 1176 3261 5.28 3.21 4.26 7.09 5.07 6.09
Open in a new tab

P-value was statistically significant between male and female groups (P< 0.05); it was 0.004, 0.003, and 0.009 for death number, incidence rate, and prevalence rate, respectively.

DALYs and its component

The estimated esophageal cancer in Iran during 1995-2015 was 304 102 DALYs. Table 2 demonstrates the number of DALYs and death due to esophageal cancer in Iran during 1995- 2015 according to age groups. As presented in the table, 50-69 age group and over 70 years age group had the highest DALYs.

Table 2. The death and DALYs number of esophageal cancer in different age groups in Iran during1995- 2015 .

DALYs Number and Rate Death Number
Age groups Female Male Total Female Male Total
Number Crude Rate per 100,000 Number Crude Rate per 100,000 Number Crude Rate per 100,000
Younger than 5 0 00 0 00 0 00 0 0 0
5-14 years 0 00 0 00 0 00 0 0 0
15-49 years 31148 25.72 37587 29.06 68735 27.4 678 816 1494
50-69 years 66003 289.66 93301 397.38 159304 344.02 2409 3438 5847
>70 years 27389 496.8 48674 788.42 76063 649.62 2092 3711 5803
All ages 124540 56.93 179562 78.81 304102 68.02 5178 7966 13144
Open in a new tab

Table 3 and Fig. 1 present the number of DALYs, YLLs, and YLDs regarding esophageal cancer by age and gender in Iran during 1995-2015. In both genders and all ages, the number of DALYs indicates a significant increase from 45018 in 1995 to 74399 in 2015.

Table 3. YLLs and YLDs of esophageal cancer in different age groups in Iran during 1995-2015 .

YLLs YLDs DALYs Cochran-Armitage test
Age Year Female Male Female Male Female Male Both Z= 1.8
P value= 0.072
15-49 years 1995 5209 5311 29 29 5238 5340 10578
50-69 years 1995 10113 14181 84 117 10197 14298 24495
>70 years 1995 3650 6156 53 86 3703 6242 9945
All ages 1995 18970 25649 167 232 19137 25881 45018
15-49 years 2000 6178 6481 40 40 6218 6521 12739
50-69 years 2000 11211 15387 102 133 11313 15520 26833
>70 years 2000 4484 7560 71 113 4555 7673 12228
All ages 2000 21873 29427 213 287 22086 29714 51800
15-49 years 2005 6966 8600 52 60 7018 8660 15680
50-69 years 2005 14190 18549 139 167 14329 18716 33045
>70 years 2005 6756 11169 113 178 6869 11347 18216
All ages 2005 27912 38319 304 406 28216 38725 66941
15-49 years 2010 6162 8185 49 61 6211 8246 14457
50-69 years 2010 13891 18994 145 182 14036 19176 33212
>70 years 2010 6658 11287 127 203 6785 11490 18275
All ages 2010 26708 38466 321 447 27030 38914 65944
15-49 years 2015 6408 8750 54 69 6462 8819 15281
50-69 years 2015 15951 25346 177 245 16128 25591 41719
>70 years 2015 5365 11701 112 221 5477 11922 17399
All ages 2015 27724 45798 342 535 28066 46333 74399
Open in a new tab

Fig. 1.

Fig. 1

Sex differentials in burden of esophageal cancer by years in Iran during 1995-2015

Open in a new tab

Data showed that YLLs are the main contributor to DALY calculations for all ages and both genders. YLLs were 44619 in 1995 and 73522 in 2015, while they were 399 in 1995 and 877 in 2015. Furthermore, YLLs were higher than YLDs in all years and all group ages.

Our findings demonstrated that the burden of esophageal cancer was higher in males than in females. Also, the overall DALYs for all years and all ages were 179 562 for males and 124 540 for females (Table 2). As displayed in Fig. 2, the DALY rate per 100 000 esophageal cancer cases during 1995-2015 was higher for males than females. In all age groups, the burden of esophageal cancer was higher in males than in females. Table 3 displays that in 2015 DALYs in all ages were 46333 for males and 28066 for females.

Fig. 2.

Fig. 2

DALY rate per 100 000 for esophageal cancer by sex during 1995-2015 in Iran

Open in a new tab

The results of this study indicated that the maximum of DALYs during 1995-2015 was associated with the 50-69 age range for which DALY values were 24495 in 1995 and 41719 in 2015. Figure 3 displays the DALYs for different age groups. As demonstrated, in all years, the 50-69 age groups had the highest DALY due to esophageal cancer in Iran. Furthermore, Table 3 displays the number of DALYs according to sex and age groups. For both genders and all years, the DALYs were higher in 50- 69 age groups than other groups.

Fig. 3.

Fig. 3

DALYs number of esophageal cancer in different age groups by years in Iran during 1995-2015

Open in a new tab

Discussion

The present study was based on GBD findings from 1995 to 2015 for all ages and both genders. Moreover, this study was the first comprehensive effort to report the burden of esophageal cancer in Iran at the general population level.

About 13144 deaths and 304 102 DALYs attributed to esophageal cancer were estimated during 1995-2015 in Iran. The present study clearly showed that DALYs, epidemiological indicators, the number of deaths, and incidence, and prevalence rate of this cancer increased significantly in both genders and all ages in Iran during the period studied. Furthermore, the number of DALYs due to esophageal cancer for both genders was 45 018 by all ages in 1995 and 74 399 in 2015. Incidence rate per 100 000 was 2.7 and 4.26 in 1995 and 2015, respectively. Prevalence rate increased from 2.96 to 6.09 per 100 000 during 1995-2015. These findings are consistent with other reports and studies. Darabi et al. estimated that the incidence rate of esophageal cancer increased from 3.25 and 2.1 in 2001 to 5.57 and 5.62 per 100 000 in 2010 (13). Another study on the incidence cancer in Iran reported that age-standardized incidence rate per 100 000 for males increased from 4.64 to 5.83 during 2003 to 2006 (30). Notably, the burden of esophageal cancer is very high in some areas of Iran, particularly in northeastern parts located on Asian esophageal cancer belt. Regional studies indicate that the incidence and prevalence rate in the mentioned area is higher than other regions and national average. Some studies have shown that the age-standardized incidence rate was more than 43.3 and 36.3 per 100 000 in males and females, respectively, in the Golestan Province in the north of Iran (9, 31).

In line with previous studies, our results indicate that YLL is the main contributor to DALY calculations, as esophageal cancer is a mortal disease. In fact, the burden of fatal diseases predominantly affects premature death. This result is consistent with other studies. For instance, in a study conducted by Sun et al. in China, it was reported that YLLs contributed to 90% of the DALYs for esophageal cancer (32). Another study reported that YLL contributed to more than 90% of DALY rate for esophageal cancer in all people (33). Gonzalez-Leon et al. estimated the burden of diseases in Mexico in 2010 and reported that YLL and YLD for esophageal cancer were 6032 and 690, respectively (34).

Our findings also revealed that the burden of esophageal cancer was higher in males than in females for all age groups. During 1995- 2015, the number of deaths was 7967 and 5177 for males and females, respectively, and DALYs number was 179 562 for males and 124 540 for females. Moreover, DALY rate related to esophageal cancer was higher in males than in females during 1995-2015 (Fig. 2). Examinations of the DALYs number based on gender and age group (Table 3) revealed that the number of DALY was higher in males than in females in all age groups. Several studies have confirmed these results (35-37).

For some reason, the burden of esophageal cancer was higher in males. According to studies conducted in Iran, more than 90% of esophageal cancers related to squamous cell carcinoma and this subtype of esophageal cancer were associated with tobacco and alcohol consumption, hot food and beverage, ingestion of N-nitroso compounds, smoking, and chewing nass (chewing tobacco mixture). Various studies in Iran have shown that these risk factors are less in females (16, 38-40). Moreover, the DALY rate per 100 000 during 2005-2015 decreased in females due to several reasons. The death number due to esophageal cancer has increased in females during 1995-2005, but it declined after 2005. Also, the incidence rate shows the same trend (Table 1). In addition, this decline could be due to changes in population structure and the mean age of females, which was less than that of males during the past years. This study showed that 35% of the changes in esophageal cancer burden during 1990- 2013 can be due to population growth and 35.6% may be due to change in age structure (41).

The acquired data indicated that the 50- 69 age group had a higher burden of disease than other groups in Iran during 1995-2015. The DALYs number for this group was 24 495 and 41 719 in 1995 and 2015, respectively. Number of DALYs was 0 for younger than 14 age group in all years. A study in China reported that patients aged 40 to 80 years account for more than 90% of total esophageal cancer DALYs (32). Studies in Iran have shown that the highest incidence of esophageal cancer is in the sixth decade of life (42-44).

There were some limitations in this study. First, GBD study does not distinguish between the burden of esophageal cancer due to adenocarcinoma of the esophagus and esophageal squamous cell carcinoma. This could be a subject for future studies, as each of these burdens has its own burden of disease. Second, the estimates of GBD study depend on the quality and quantity of the available data sources because of the lag time for data reporting. The burden of cancers could not be estimated for countries that do not have a comprehensive system for registering and reporting cancers. For example, studies have shown that incidence and prevalence of esophageal cancer were much higher than estimates of GBD study in some regions of Iran (9, 45).

Conclusion

Esophageal cancer is still a public health problem in Iran. The majority of DALYs were due to years of life lost (YLL), suggesting the need for prevention, early detection, and screening programs. Since the findings of this study and those of others have shown that the burden of esophageal cancer is greater in the 50-69 age group and given that the young Iranian population is approaching the at-risk age group, policymakers should evaluate the future tasks among different health care sections by considering prevention, early detection, approaching, and rehabilitation.

Acknowledgment

We thank the Institute for Health Metric and Evaluation (IHME) team for providing the data of GBD studies.

Conflict of Interests

The authors declare that they have no competing interests.

Cite this article as: Rahmani H, Sarabi Asiabar A, Niakan S, Hashemi SY, Faramarzi A, Manuchehri S, Rajabi Vasokolaei Gh. Burden of esophageal cancer in Iran during 1995-2015: Review of findings from the global burden of disease studies. Med J Islam Repub Iran. 2018 (2 Jul);32:55. https://doi.org/10.14196/mjiri.32.55

References

  • 1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86. doi: 10.1002/ijc.29210. [DOI] [PubMed] [Google Scholar]
  • 2. Global Burden of Disease Study 2015. [Internet]. 2015 [cited Available from http://ghdx.healthdata.org/gbd-results-tool.].
  • 3.Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030. Am J Gastroenterol. 2017 doi: 10.1038/ajg.2017.155. [DOI] [PubMed] [Google Scholar]
  • 4.Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G. et al. Barrett's esophagus and esophageal cancer: an overview. Int J Oncol. 2012;41(2):414–24. doi: 10.3892/ijo.2012.1481. [DOI] [PubMed] [Google Scholar]
  • 5.Mansour-Ghanaei F, Heidarzadeh A, Naghipour MR, Joukar F, Valeshabad AK, Fallah MS. et al. A 10-year study of esophageal cancer in Guilan Province, Iran: the guilan cancer registry study (GCRS) Asian Pac J Cancer Prev. 2012;13(12):6277–83. doi: 10.7314/apjcp.2012.13.12.6277. [DOI] [PubMed] [Google Scholar]
  • 6.Islami F, Malekshah AF, Kimiagar M, Pourshams A, Wakefield J, Goglani G. et al. Patterns of food and nutrient consumption in northern Iran, a high-risk area for esophageal cancer. Nutr Cancer . 2009;61(4):475–83. doi: 10.1080/01635580902803735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B. et al. Socio-economic status and oesophageal cancer: results from a population-based case–control study in a high-risk area. Int J Epidemiol. 2009;38(4):978–88. doi: 10.1093/ije/dyp195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Semnani S, Sadjadi A, Fahimi S, Nouraie M, Naeimi M, Kabir J. et al. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran: a retrospective cancer surveillance. Cancer Detect Prev. 2006;30(1):14–9. doi: 10.1016/j.cdp.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 9.Sadjadi A, Marjani H, Semnani S, Nasseri-Moghaddam S. Esophageal cancer in Iran: A review. Middle East J Cancer. 2010;1(1):5–14. [Google Scholar]
  • 10.Harirchi I, Kolahdoozan S, Hajizadeh S, Safari F, Sedighi Z, Nahvijou A. et al. Esophageal cancer in Iran; a population-based study regarding adequacy of cancer surgery and overall survival. Eur J Surg Oncol (EJSO) 2014;40(3):352–7. doi: 10.1016/j.ejso.2013.10.011. [DOI] [PubMed] [Google Scholar]
  • 11.Mir MR, Rajabpour MV, Delarestaghi MM, Hadji M, Harirchi I, Mir P. et al. Short-and long-term survival of esophageal cancer patients treated at the Cancer Institute of Iran. Dig Surg. 2013;30(4-6):331–6. doi: 10.1159/000354854. [DOI] [PubMed] [Google Scholar]
  • 12.De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34. doi: 10.1016/S1470-2045(13)70546-1. [DOI] [PubMed] [Google Scholar]
  • 13.Darabi M, Lari MA, Motevalian SA, Motlagh A, Arsang-Jang S, Jaberi MK. Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis. Epidemiol Health. 2016:38. doi: 10.4178/epih.e2016056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Almasi Z, Mohammadian-Hafshejani A, Salehiniya H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON. 2016;21(4):994–1004. [PubMed] [Google Scholar]
  • 15.Momenyan S, Sadeghifar M, Sarvi F, Khodadost M, Mosavi-Jarrahi A, Ghaffari ME. et al. Relationship between Urbanization and Cancer Incidence in Iran Using Quantile Regression Asian Pac J. Cancer Prev. 2016;17(S3):113–7. doi: 10.7314/apjcp.2016.17.s3.113. [DOI] [PubMed] [Google Scholar]
  • 16.Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J  Cancer Prev. 2006;7(3):375. [PubMed] [Google Scholar]
  • 17.Mousavi SM, Somi MH. Gastric cancer in Iran 1966-2006 Asian Pac J. Cancer Prev. 2009;10(3):407–12. [PubMed] [Google Scholar]
  • 18.Salehi M, Ahmadi E, Roshandel G, Heidarnia M, Keshtkar A, Sajadi A. et al. Total Burden of Esophageal Cancer Disability Adjusted Life Years in Golestan Province during 1387. Govaresh. 2011;15(4):276–82. [Google Scholar]
  • 19.Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. lancet. 2013;380(9859):2197–223. doi: 10.1016/S0140-6736(12)61689-4. [DOI] [PubMed] [Google Scholar]
  • 20.Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A. et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2071–94. doi: 10.1016/S0140-6736(12)61719-X. [DOI] [PubMed] [Google Scholar]
  • 21.Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100(5-6):481–99. doi: 10.1179/136485906X97417. [DOI] [PubMed] [Google Scholar]
  • 22. Lopez A, Mathers C, Ezzati M, Jamison D, Murray C. Global Burden of Disease and Risk Factors: A copublication of Oxford University Press and The World Bank. 2006. [PubMed]
  • 23. WHO methods and data sources for global burden of disease estimates 2000-2015. Department of Information EaRW, Geneva; 2017.
  • 24.Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions Bull. World Health Organ. 1994;72(3):495. [PMC free article] [PubMed] [Google Scholar]
  • 25. Sassi F. Calculating QALYs and DALYs: methods and applications to fatal and non-fatal conditions. Handbook of Disease Burdens and Quality of Life Measures: Springer; 2010. p. 313-28.
  • 26. Lopez AD. Global burden of disease and risk factors: World Bank Publications; 2006. [PubMed]
  • 27. WHO G. WHO methods and data sources for global burden of disease estimates 2000-2011. Geneva: Department of Health Statistics and Information Systems. 2013.
  • 28.Gabbe BJ, Lyons RA, Simpson PM, Rivara FP, Ameratunga S, Polinder S. et al. Disability weights based on patient-reported data from a multinational injury cohort Bull. World Health Organ. 2016;94(11):806. doi: 10.2471/BLT.16.172155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. Geneva: World Health Organization 2001;9.
  • 30.Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63. doi: 10.1093/annonc/mdn642. [DOI] [PubMed] [Google Scholar]
  • 31.Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10(1):70–82. [PubMed] [Google Scholar]
  • 32.Sun X, Zhao D, Liu Y, Liu Y, Yuan Z, Wang J. et al. The long-term spatial-temporal trends and burden of esophageal cancer in one high-risk area: A population-registered study in Feicheng, China. PLoS ONE. 2017;12(3):e0173211. doi: 10.1371/journal.pone.0173211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jayatilleke N, Pashayan N, Powles J. Burden of disease due to cancer in England and Wales. J Public Health (Oxf) 2012;34(2):287–95. doi: 10.1093/pubmed/fdr093. [DOI] [PubMed] [Google Scholar]
  • 34.González-León M, Fernández-Gárate JE, Rascón-Pacheco RA, Valladares-Aranda MÁ, Dávila-Torres J, Borja-Aburto VH. The burden of disease of cancer in the Mexican Social Security Institute. Salud Publica Mex. 2016;58(2):132–41. doi: 10.21149/spm.v58i2.7781. [DOI] [PubMed] [Google Scholar]
  • 35.Traebert J, Schneider IJC, Colussi CF, de Lacerda JT. Burden of disease due to cancer in a Southern Brazilian state. Cancer Epidemiol. 2013;37(6):788–92. doi: 10.1016/j.canep.2013.08.007. [DOI] [PubMed] [Google Scholar]
  • 36.Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X. et al. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 2013;5(1):19–26. doi: 10.3978/j.issn.2072-1439.2013.01.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. doi: 10.1001/jamaoncol.2016.5688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83. [PubMed] [Google Scholar]
  • 39.Sepehr A, Kamangar F, Fahimi S, Saidi F, Abnet CC, Dawsey SM. Poor oral health as a risk factor for esophageal squamous dysplasia in northeastern Iran. Anticancer Res. 2005;25(1B):543–6. [PubMed] [Google Scholar]
  • 40.Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R. et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. Bmj. 2009;338:b929. doi: 10.1136/bmj.b929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF. et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27. doi: 10.1001/jamaoncol.2015.0735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Semnani Sh, Arabali A, Keshtkar A, Behnampoor N. Nitrate and nitrite level of drinking water and the risk of upper gastrointestinal cancers in urban areas of Golestan province, northeast of Iran. JKMU. 2015.
  • 43.Semnani S, Besharat S, Abdolahi N, Keshtkar A, Kabir M, Fazel A. et al. Factors associated with esophageal cancer in the southeast part of the Caspian Sea. Jour guilan uni med sci. 2005;13(52):24–8. [Google Scholar]
  • 44.Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, Nasrollahzadeh D. et al. Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med. 2007;10(1):32–7. [PubMed] [Google Scholar]
  • 45.Radmard AR. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143. [PubMed] [Google Scholar]

Articles from Medical Journal of the Islamic Republic of Iran are provided here courtesy of Iran University of Medical Sciences

RESOURCES